Complement activation in patients with neuromyelitis optica.

Abstract

The role of complement has been demonstrated in experimental models of neuromyelitis optica (NMO), however, only few studies have analysed complement components longitudinally in NMO patients. We measured serum or plasma concentrations of anti-C1q antibodies and complement split products C3a and C4a and soluble C5b-9 in patients with NMO, multiple sclerosis and healthy controls. NMO patients had higher levels of C3a and anti-C1q antibodies than healthy controls. C3a levels correlated with disease activity, neurological disability and aquaporin-4 IgG in NMO patients suggesting a role of the alternative pathway of complement in the pathogenesis of NMO and supporting the strategy of therapeutic complement inhibition.

• Authors: Petra Nytrova, Eliska Potlukova, David Kemlink, Mark Woodhall, Dana Horakova, Patrick Waters, Eva Havrdova, Dana Zivorova, Angela Vincent, Marten Trendelenburg
• Journal: Journal of neuroimmunology (J Neuroimmunol) Vol. 274 Issue 1-2 Pg. 185-91 (Sep 15 2014) ISSN: 1872-8421 [Electronic] Netherlands
• PMID: 25109258 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2014 Elsevier B.V. All rights reserved.

Chemical References

• AQP4 protein, human
• Aquaporin 4
• Autoantibodies
• Immunoglobulin G
• Complement C1q
• Complement C3a

Topics

• Adolescent
• Adult
• Aged
• Aquaporin 4 (immunology)
• Autoantibodies (blood, immunology)
• Complement Activation (immunology)
• Complement C1q (immunology, metabolism)
• Complement C3a (immunology, metabolism)
• Female
• Follow-Up Studies
• Humans
• Immunoglobulin G (blood, immunology)
• Male
• Middle Aged
• Multiple Sclerosis, Relapsing-Remitting (immunology)
• Neuromyelitis Optica (immunology)
• Prospective Studies
• Young Adult